Cheaper Alternative to Rybelsus for Weight Loss and Blood Sugar Control – Safer Alternatives to take...
Daily Sundial· 32 minutes agoRybelsus is a pill form version of semaglutide – an FDA approved prescribed medication to manage...
Prevention better than cure in race to slash rates of TB, global review finds
Medical Xpress· 3 hours agoThe first global review of the effectiveness of current strategies to fight tuberculosis—the leading...
IFF Spotlights Pioneering Dietary Supplement Innovations at SupplySide West 2023
WAVE 3 Louisville· 4 hours agoIFF's Pharma Solutions and Health teams will showcase their extensive portfolios of next-level, plant-based dietary supplement solutions and innovative combination products that address some ...
ChatGPT can hurt employee performance when used on the wrong tasks
Fortune· 4 hours agoA new study from Boston Consulting Group’s Henderson Institution think tank and academics at four...
Montana’s Ban on Transition Care for Minors Is Blocked
New York Times· 46 minutes agoA state judge in Montana on Wednesday temporarily blocked a law that would have banned transition care for children under 18 starting on Sunday, while a lawsuit filed by patients and medical ...
Nasal spray to rival EpiPen delayed over efficacy concerns
Daily Telegraph· 1 day agoA nasal spray that could save the lives of thousands of people with severe allergies will face further testing due to concerns over its effectiveness. In the UK and countries all around the ...
Insurtech MGA Loadsure Partners With WeatherOptics to Boost Cargo Risk Calculations
Insurance Journal· 8 hours agoBy utilizing WeatherOptics’ technology, Loadsure will enhance the resolution of their rating...
NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2023 SITC Annual Meeting
Black Hills FOX· 4 hours agoNeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced it will present development progress of its main asset, NT-I7 (efineptakin ...
Aitia and Pancreatic Cancer Action Network Partner to Transform De-Identified Multi-Omic Patient...
Morningstar· 37 minutes agoLOS ANGELES and SOMERVILLE, Ma., Sept. 27, 2023 /PRNewswire/ -- Aitia, the leader in the development and application of Causal AI and Digital Twins to discover and develop new drugs, today announced a collaboration with the Pancreatic Cancer Action
EvokAI Creative Labs Initiates CE Mark Certification for Innovative Parkinson’s Disease Technology
Digital Journal· 4 hours agoThis is especially valuable in the current era of telemedicine. Clinical Validation: EvokAI has conducted rigorous clinical trials and studies to validate the safety and efficacy< ...
Yahoo Web Search
Trending Now
